|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
Statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Sorber L, Zwaenepoel K, Deschoolmeester V,
Van Schil PE, Van Meerbeeck J, Lardon F, Rolfo C and Pauwels P:
Circulating cell-free nucleic acids and platelets as a liquid
biopsy in the provision of personalized therapy for lung cancer
patients. Lung Cancer. 107:100–107. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Gan Y, Zhou P and Li W: Correlations of
Tumor Stage and Serum Tumor Markers with Age in Nonsmoking Females
with Lung Adenocarcinoma. D62 types, Genotypes, and Phenotypes: The
Three Ts of thoracic oncology. American Thoracic Society; pp.
ppA73342018
|
|
4
|
Zhai X, Zheng Q, Yang L, Zhu Y, Li J, Liu
Y and Wang Y: Impact of platinum/pemetrexed combination versus
other platinum-based regimens on adjuvant chemotherapy in resected
lung adenocarcinoma. Sci Rep. 7:14532017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Jin B, Niu Y, Zhang Y, Chu T, Gu A, Wu J,
Pei J, Zhu L and Han B: 1281Pcombination of chemotherapy and
gefitinib as first-line treatment of patients with advanced lung
adenocarcinoma and sensitive egfr mutations: A randomised
controlled trial. Ann Oncol. 25 (4 Suppl):iv4512014. View Article : Google Scholar
|
|
6
|
Xu R, Mao Y, Chen K, He W, Shi W and Han
Y: The long noncoding RNA ANRIL acts as an oncogene and contributes
to paclitaxel resistance of lung adenocarcinoma A549 cells.
Oncotarget. 8:39177–39184. 2017.PubMed/NCBI
|
|
7
|
Sato C, Okuda K, Tamiya H, Yamamoto K,
Hoshina K, Narumoto O, Urushiyama H, Noguchi S, Amano Y, Watanabe
K, et al: Acute arterial thrombosis during postoperative adjuvant
cisplatin-based chemotherapy for completely resected lung
adenocarcinoma. Intern Med. 57:557–561. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wang Q, Cheng N, Li X, Pan H, Li C, Ren S,
Su C, Cai W, Zhao C, Zhang L and Zhou C: Correlation of long
non-coding RNA H19 expression with cisplatin-resistance and
clinical outcome in lung adenocarcinoma. Oncotarget. 8:2558–2567.
2017.PubMed/NCBI
|
|
9
|
Raz DJ, Zell JA, Ou SH, Gandara DR,
Anton-Culver H and Jablons DM: Natural history of stage Inon-small
cell lung cancer:Implications for early detection. Chest.
132:193–199. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Roselli M, Mariotti S, Ferroni P, Laudisi
A, Mineo D, Pompeo E, Ambrogi V and Mineo TC: Postsurgical
chemotherapy in stage IB non-small cell lung cancer: Long-term
survival in a randomized study. Int J Cancer. 119:955–960. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
García SA, Weitz J and Schölch S:
Circulating tumor cells. Cancer stem cells: Methods and protocols.
Papaccio G and Desiderio V: Springer; New York, NY: pp. 213–219.
2018, View Article : Google Scholar
|
|
12
|
Yu M, Bardia A, Wittner BS, Stott SL, Smas
ME, Ting DT, Isakoff SJ, Ciciliano JC, Wells MN, Shah AM, et al:
Circulating breast tumor cells exhibit dynamic changes in
epithelial and mesenchymal composition. Science. 339:580–584. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kallergi G, Papadaki MA, Politaki E,
Mavroudis D, Georgoulias V and Agelaki S: Epithelial to mesenchymal
transition markers expressed in circulating tumour cells of early
and metastatic breast cancer patients. Breast Cancer Res.
13:R592011. View
Article : Google Scholar : PubMed/NCBI
|
|
14
|
Giuliano M, Giordano A, Jackson S, Hess
KR, De Giorgi U, Mego M, Handy BC, Ueno NT, Alvarez RH and De
Laurentiis M: Circulating tumor cells as prognostic and predictive
markers in metastatic breast cancer patients receiving first-line
systemic treatment. Breast Cancer Res. 13:R672011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Pierga JY, Hajage D, Bachelot T, Delaloge
S, Brain E, Campone M, Diéras V, Rolland E, Mignot L, Mathiot C and
Bidard FC: High independent prognostic and predictive value of
circulating tumor cells compared with serum tumor markers in a
large prospective trial in first-line chemotherapy for metastatic
breast cancer patients. Ann Oncol. 23:618–624. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yokobori T, Iinuma H, Shimamura T, Imoto
S, Sugimachi K, Ishii H, Iwatsuki M, Ota D, Ohkuma M, Iwaya T, et
al: Plastin3 is a novel marker for circulating tumor cells
undergoing the epithelial-mesenchymal transition and is associated
with colorectal cancer prognosis. Cancer Res. 73:2059–2069. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lianidou ES, Markou A and Strati A: The
role of CTCs as tumor biomarkers. Adv Exp Med Biol. 867:341–367.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Xia H, Ooi LL and Hui KM:
MicroRNA-216a/217-induced epithelial-mesenchymal transition targets
PTEN and SMAD7 to promote drug resistance and recurrence of liver
cancer. Hepatology. 58:629–641. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhu W, Zhu D, Lu S, Wang T, Wang J, Jiang
B, Shu Y and Liu P: miR-497 modulates multidrug resistance of human
cancer cell lines by targeting BCL2. Med Oncol. 29:384–391. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhu W, Xu H, Zhu D, Zhi H, Wang T, Wang J,
Jiang B, Shu Y and Liu P: miR-200bc/429 cluster modulates multidrug
resistance of human cancer cell lines by targeting BCL2 and XIAP.
Cancer Chemother Pharmacol. 69:723–731. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Chen QY JD, Wang J, Hu H, Tang X, Chen J,
Mou H and Lu W: miR-206 regulates cisplatin resistance and EMT in
human lung adenocarcinoma cells partly by targeting MET.
Oncotarget. 7:24510–24526. 2016.PubMed/NCBI
|
|
22
|
Zhao Z, Zhang L, Yao Q and Tao Z: miR-15b
regulates cisplatin resistance and metastasis by targeting PEBP4 in
human lung adenocarcinoma cells. Cancer Gene Ther. 22:108–114.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kitamura K, Seike M, Okano T, Matsuda K,
Miyanaga A, Mizutani H, Noro R, Minegishi Y, Kubota K and Gemma A:
MiR-134/487b/655 cluster regulates TGF-β-induced
epithelial-mesenchymal transition and drug resistance to gefitinib
by targeting MAGI2 in lung adenocarcinoma cells. Mol Cancer Ther.
13:444–453. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ujifuku K, Mitsutake N, Takakura S,
Matsuse M, Saenko V, Suzuki K, Hayashi K, Matsuo T, Kamada K,
Nagata I and Yamashita S: miR-195, miR-455-3p and miR-10a(*) are
implicated in acquired temozolomide resistance in glioblastoma
multiforme cells. Cancer Lett. 296:241–248. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Bao M, Pan S, Yang W, Chen S, Shan Y and
Shi H: Serum mir-10a-5p and mir-196a-5p as non-invasive biomarkers
in non-small cell lung cancer. Int J Clin Exp Pathol. 11:773–780.
2018.PubMed/NCBI
|
|
26
|
Liu Y, Xu N, Liu B, Huang Y, Zeng H, Yang
Z, He Z and Guo H: Long noncoding RNA RP11-838N2.4 enhances the
cytotoxic effects of temozolomide by inhibiting the functions of
miR-10a in glioblastoma cell lines. Oncotarget. 7:43835–43851.
2016.PubMed/NCBI
|
|
27
|
Sun W, Ma Y, Chen P and Wang D:
MicroRNA-10a silencing reverses cisplatin resistance in the
A549/cisplatin human lung cancer cell line via the transforming
growth factor-β/Smad2/STAT3/STAT5 pathway. Mol Med Rep.
11:3854–3859. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Gong C, Liu B, Yao Y, Qu S, Luo W, Tan W,
Liu Q, Yao H, Zou L, Su F and Song E: Potentiated DNA damage
response in circulating breast tumor cells confers resistance to
chemotherapy. J Biol Chem. 290:14811–14825. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) methods. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Damavandi Z, Torkashvand S, Vasei M,
Soltani BM, Tavallaei M and Mowla SJ: Aberrant expression of breast
development-related MicroRNAs, miR-22, miR-132, and miR-212, in
breast tumor tissues. J Breast Cancer. 19:148–155. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Ma L, Teruya-Feldstein J and Weinberg RA:
Tumour invasion and metastasis initiated by microRNA-10b in breast
cancer. Nature. 449:682–688. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Yan Y, Wang Q, Yan XL, Zhang Y, Li W, Tang
F, Li X and Yang P: miR-10a controls glioma migration and invasion
through regulating epithelial-mesenchymal transition via EphA8.
FEBS Lett. 589:756–765. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Wang Y, Liu Z, Yao B, Dou C, Xu M, Xue Y,
Ding L, Jia Y, Zhang H and Li Q: Long non-coding RNA TUSC7 acts a
molecular sponge for miR-10a and suppresses EMT in hepatocellular
carcinoma. Tumour Biol. 37:11429–11441. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Weiss FU, Marques IJ, Woltering JM,
Vlecken DH, Aghdassi A, Partecke LI, Heidecke CD, Lerch MM and
Bagowski CP: Retinoic acid receptor antagonists inhibit miR-10a
expression and block metastatic behavior of pancreatic cancer.
Gastroenterology. 137:2136–2145.e1-7. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Bryant A, Palma CA, Jayaswal V, Yang YW,
Lutherborrow M and Ma DD: miR-10a is aberrantly overexpressed in
Nucleophosmin1 mutated acute myeloid leukaemia and its suppression
induces cell death. Mol Cancer. 11:82012. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Yu T, Liu L, Li J, Yan M, Lin H, Liu Y,
Chu D, Tu H, Gu A and Yao M: MiRNA-10a is upregulated in NSCLC and
may promote cancer by targeting PTEN. Oncotarget. 6:30239–30250.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Janku F, Wheler JJ, Westin SN, Moulder SL,
Naing A, Tsimberidou AM, Fu S, Falchook GS, Hong DS, Garrido-Laguna
I, et al: PI3K/AKT/mTOR inhibitors in patients with breast and
gynecologic malignancies harboring PIK3CA mutations. J Clin Oncol.
30:777–782. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Woo SU, Sangai T, Akcakanat A, Chen H, Wei
C and Meric-Bernstam F: Vertical inhibition of the PI3K/Akt/mTOR
pathway is synergistic in breast cancer. Oncogenesis. 6:e3852017.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Chai R, Fu H, Zheng Z, Liu T, Ji S and Li
G: Resveratrol inhibits proliferation and migration through SIRT1
mediated post-translational modification of PI3K/AKT signaling in
hepatocellular carcinoma cells. Mol Med Rep. 16:8037–8044. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Hu R, Pan W, Fedulov AV, Jester W, Jones
MR, Weiss ST, Panettieri RA Jr, Tantisira K and Lu Q: MicroRNA-10a
controls airway smooth muscle cell proliferation via direct
targeting of the PI3 kinase pathway. FASEB J. 28:2347–2357. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Ke K and Lou T: MicroRNA-10a suppresses
breast cancer progression via PI3K/Akt/mTOR pathway. Oncol Lett.
14:5994–6000. 2017.PubMed/NCBI
|
|
42
|
Zhao G, Cai C, Yang T, Qiu X, Liao B, Li
W, Ji Z, Zhao J, Zhao H, Guo M, et al: MicroRNA-221 induces cell
survival and cisplatin resistance through PI3K/Akt pathway in human
osteosarcoma. PLoS One. 8:e539062013. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Shao XJ, Miao MH, Xue J, Xue J, Ji XQ and
Zhu H: The Down-regulation of MicroRNA-497 contributes to cell
growth and cisplatin resistance through PI3K/Akt pathway in
osteosarcoma. Cell Physiol Biochem. 36:2051–2062. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Wang Y, Chen L, Huang G, He D, He J, Xu W,
Zou C, Zong F, Li Y, Chen B, et al: Klotho sensitizes human lung
cancer cell line to cisplatin via PI3k/Akt pathway. PLoS One.
8:e573912013. View Article : Google Scholar : PubMed/NCBI
|
